Zoliflodacin is under clinical development by Entasis Therapeutics Holdings and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Zoliflodacin’s likelihood of approval (LoA) and phase transition for Uncomplicated Cervical And Urethral Gonorrhea took place on 29 Aug 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Zoliflodacin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Zoliflodacin overview
Zoliflodacin (ETX-0914 (formerly AZD-0914)) is under development for the treatment of drug-resistant uncomplicated cervical and urethral gonorrhea. The drug candidate is administered through oral route as an antimicrobial amorphous nonsterile powder. The drug candidate is a benzisoxazole derivative and it acts by targeting ATP pocket of DNA gyrase and topoisomerase IV.
Entasis Therapeutics Holdings overview
Entasis Therapeutics Holdings (Entasis) is a drug development company. It discovers and develops anti-infective therapies for drug-resistant bacterial infections. The company’s pipeline products include ETX2514, ETX0282, ETX0462 and Zoliflodacin. Its ETX2514 product is a potent inhibitor of class A, C, and D beta-lactamases intended to treat serious gram-negative infections. The company’s pipeline products are used to treat multidrug-resistant gram-negative infections such as pseudomonas aeruginosa, acinetobacter baumanii, carbapenem-resistant enterobacteriaceae, and neisseria gonorrhoeae, among others. It also develops robust clinical and pre-clinical pipeline of medicines. Entasis is headquartered in Waltham, Massachusetts, the US.
Quick View Zoliflodacin LOA Data
Report Segments |
|
Drug Name |
|
Administration Pathway |
|
Therapeutic Areas |
|
Key Developers |
|
Highest Development Stage |
|